The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer (Q87691736)

From Wikidata

Jump to navigation Jump to search

scientific article published on 15 April 2014

Language	Label	Description	Also known as
English	The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer	scientific article published on 15 April 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

The Bim deletion polymorphism clinical profile and its relation with tyrosine kinase inhibitor resistance in Chinese patients with non-small cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

non-small-cell lung carcinoma

1 reference

based on heuristic

inferred from title

11

object named as

Caicun Zhou

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

author name string

Mingchuan Zhao

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Yishi Zhang

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Weijing Cai

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Jiayu Li

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Fei Zhou

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ningning Cheng

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Ruixin Ren

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Chao Zhao

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Xuefei Li

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Shengxiang Ren

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Fred R Hirsch

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

publication date

15 April 2014

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

120

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

2299-2307

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR antagonists in cancer treatment

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Apoptosis and autophagy: BIM as a mediator of tumour cell death in response to oncogene-targeted therapeutics

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of BIM is essential for apoptosis triggered by EGFR kinase inhibitors in mutant EGFR-dependent lung adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib and nilotinib induce apoptosis of chronic myeloid leukemia cells through a Bim-dependant pathway modulated by cytokines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Apoptosis Induction by MEK Inhibition in Human Lung Cancer Cells Is Mediated by Bim

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Screening for epidermal growth factor receptor mutations in lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.28725

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.28725

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24737648%20AND%20SRC:MED&resulttype=core&format=json

14 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q87691736&oldid=2147350488"